• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Teleflex Incorporated filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/15/25 4:06:35 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email
    tfx-20250509
    0000096943false12/3100000969432025-05-092025-05-09

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of Earliest Event Reported) May 9, 2025

    TELEFLEX INCORPORATED
    (Exact name of Registrant as Specified in Its Charter)
    Delaware1-535323-1147939
    (State or Other Jurisdiction
    of Incorporation or Organization)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    550 E. Swedesford Rd., Suite 400Wayne,PA19087
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code(610)225-6800
    Not applicable
    (Former Name or Former Address, If Changed Since Last Report)
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $1 per shareTFXNew York Stock Exchange


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On May 9, 2025, the Board of Directors of Teleflex Incorporated (the “Company”) approved the amendment and restatement of the Company’s Third Amended and Restated Bylaws (the bylaws, as amended and restated, the “Fourth Amended and Restated Bylaws”). The only change effected by the amendment and restatement is to delete former Section 2.2.5, which required that that any action taken by the stockholders of the Company be effected at a duly called annual or special meeting of the stockholders and specifically prohibited stockholders from action by consent in writing or by telephone.

    The Fourth Amended and Restated Bylaws are filed as Exhibit 3.1 to this Current Report on Form 8-K.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    (a) The Company held its 2025 annual meeting of stockholders on May 9, 2025 (the “2025 Annual Meeting”). At the 2025 Annual Meeting, the Company’s stockholders voted on:

    •the election of nine directors of the Company to serve for a term of one year or until their successors have been duly elected and qualified;

    •the approval, on an advisory basis, of the compensation of the Company’s named executive officers;

    •the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2025; and

    •a stockholder proposal regarding the continuous holding requirement for calling a special stockholder meeting.

    (b) The final voting results with respect to each proposal are set forth below.

    1.    Election of Directors

    NameForAgainstAbstainBroker Non-Votes
    Candace H. Duncan28,443,19411,086,83279,2541,581,320
    Gretchen R. Haggerty28,674,81610,856,09778,3671,581,320
    John C. Heinmiller28,666,24810,852,28490,7481,581,320
    Liam J. Kelly27,397,53412,132,75278,9941,581,320
    Stephen K. Klasko25,382,68614,145,38081,2141,581,320
    Andrew A. Krakauer28,199,51511,327,84581,9201,581,320
    Neena M. Patil28,590,30410,910,246108,7301,581,320
    Stuart A. Randle27,030,09112,493,93185,2581,581,320
    Jaewon Ryu28,204,94311,320,04584,2921,581,320
    2.    Advisory Vote on Compensation of Named Executive Officers

    ForAgainstAbstainBroker Non-Votes
    29,026,27510,444,796138,2091,581,320






    3.    Ratification of Appointment of Independent Registered Public Accounting Firm

    ForAgainstAbstainBroker Non-Votes
    39,677,8531,440,78471,9640


    4.    Stockholder Proposal Regarding the Continuous Holding Requirement for Calling a Special Stockholder Meeting

    ForAgainstAbstainBroker Non-Votes
    4,621,96934,842,111145,2001,581,320

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit NumberTitle
    3.1*-
    Fourth Amended and Restated Bylaws of Teleflex Incorporated, effective May 9, 2025.
    104-The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL.
    *Filed herewith.

    Date: May 15, 2025
    TELEFLEX INCORPORATED


    By: /s/ Daniel V. Logue
    Name: Daniel V. Logue
    Title: Corporate Vice President,
    General Counsel and Secretary


    Get the next $TFX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy

    Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for purchase in Japan, effective immediately following regulatory approval, insurance coverage acceptance and appropriate use criteria issuance by Japanese academic societies. First cases commenced earlier this month following the approval from the Japanese Pharmaceuticals and Medical Devic

    8/19/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Quarterly Dividend

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiolo

    7/31/25 6:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year period 2025 guidance summary (inclusive of the recently closed BIOTRONIK Vascular Intervention business) Raising GAAP revenue growth guidance range to 9.00% to 10.00% Raisi

    7/31/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teleflex downgraded by BofA Securities with a new price target

    BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

    3/4/25 7:44:32 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

    2/28/25 7:34:55 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by Raymond James

    Raymond James downgraded Teleflex from Outperform to Mkt Perform

    2/28/25 7:34:03 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/14/24 1:28:29 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/8/24 10:29:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    2/14/24 10:04:36 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    SEC Filings

    View All

    SEC Form 10-Q filed by Teleflex Incorporated

    10-Q - TELEFLEX INC (0000096943) (Filer)

    7/31/25 11:05:11 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TELEFLEX INC (0000096943) (Filer)

    7/31/25 7:00:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form 11-K filed by Teleflex Incorporated

    11-K - TELEFLEX INC (0000096943) (Filer)

    6/27/25 2:33:24 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Financials

    Live finance-specific insights

    View All

    Teleflex Announces Quarterly Dividend

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiolo

    7/31/25 6:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year period 2025 guidance summary (inclusive of the recently closed BIOTRONIK Vascular Intervention business) Raising GAAP revenue growth guidance range to 9.00% to 10.00% Raisi

    7/31/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Second Quarter 2025 Earnings Conference Call Information

    WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (al

    7/17/25 6:30:07 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    View All

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

    WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

    2/27/25 6:36:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care